A clinical evidence summary of BPC-157 pentadecapeptide for tendon repair, including preclinical trial data, proposed mechanisms, dosing protocols used in research, and what physicians should know about this off-label peptide.
A clinical review of CJC-1295 (modified GRF 1-29) for fat loss, including the limited trial data, mechanism of action through GH-axis stimulation, dosing protocols used in research, and why this peptide remains off-label with no FDA approval for any indication.
CJC-1295 modified GRF is used off-label for longevity. This guide covers dosing protocols, evidence quality, GH-axis physiology, safety data, and what the clinical research actually shows.
CJC-1295 (modified GRF 1-29) is used off-label for longevity and anti-aging. This evidence review covers the clinical data, monitoring requirements, safety signals, and what patients should discuss with their provider.
A clinical review of CJC-1295 (modified GRF 1-29) for recovery, including off-label evidence, GH-axis pharmacology, dosing protocols, and safety data.
Enclomiphene citrate is sometimes used off-label for gynecomastia. Learn about the evidence, dosing protocols, and how it compares to other SERMs like tamoxifen and raloxifene.
A clinical evidence summary of enclomiphene citrate used off-label for gynecomastia, including mechanism of action, trial data, dosing protocols, and how it compares to clomiphene and tamoxifen.
Evidence-based guide to off-label enclomiphene citrate use in secondary hypogonadism, including dosing protocols, clinical trial data, and comparison to clomiphene and TRT.
Enclomiphene citrate is used off-label for secondary hypogonadism to raise testosterone while preserving fertility. What the evidence actually shows, what remains unverified, and how monitoring should be structured.
Off-label finasteride helped hair density in postmenopausal women at doses above 1 mg; the 1 mg male dose showed no benefit. Contraindicated in pregnancy.
Finasteride isn't FDA-approved for women, but doctors prescribe 1-5mg off-label for female pattern hair loss with strict pregnancy testing and lab monitoring.
Off-label finasteride (2.5-5mg) may help postmenopausal women with FPHL; contraindicated in pregnancy due to fetal risk. Results take 12-18 months.
Finasteride is used off-label for hirsutism in women. Review the clinical trial data, side-effect profile, pregnancy contraindication, dosing, and how it compares to spironolactone.
Copper tripeptide GHK-Cu is used off-label for hair growth. Review the preclinical evidence, limited human data, safety risks, and how it compares to FDA-approved options like minoxidil and finasteride.
A clinical review of copper tripeptide GHK-Cu for skin regeneration, including off-label status, trial evidence, safety profile, and how it compares to FDA-approved alternatives.
A clinical evidence summary of ipamorelin acetate for fat loss, including trial data, mechanism of action, dosing protocols, safety profile, and off-label status.
Ipamorelin acetate is used off-label for longevity and anti-aging. This evidence-based guide covers dosing protocols, growth hormone physiology, safety data, and what the clinical research actually shows.
Ipamorelin acetate is used off-label for longevity and anti-aging. Learn what the evidence actually shows, how clinicians monitor patients, and what blood work is required.
A clinical review of ipamorelin acetate used off-label for recovery, including evidence quality, dosing protocols, required lab monitoring, and safety considerations.
A clinical evidence summary of metformin's off-label use for cancer prevention, including key trials, biological mechanisms, and current guideline positions.
Metformin is FDA-approved for type 2 diabetes, but observational data suggest it may reduce cancer incidence. Here is what the trials show, what remains unproven, and how to monitor patients using metformin off-label for cancer risk reduction.
Metformin is prescribed off-label for longevity based on observational data and preclinical evidence. Here is what the clinical trials show, how physicians dose it, and what TAME will tell us.
TAME trial is still ongoing, no FDA approval yet. See required labs for off-label metformin use: eGFR, B12, lactate, liver panel and glucose intervals.
A clinical review of metformin's off-label use for longevity, including trial data, AMPK mechanisms, side effects, and who may or may not benefit from anti-aging metformin therapy.
Metformin is sometimes used off-label for nonalcoholic fatty liver disease (NAFLD). Learn what the evidence shows, how monitoring works, and what guidelines recommend.
Metformin is widely prescribed off-label for NAFLD, but clinical trials show limited histological benefit. Learn the real evidence, risks, tradeoffs, and better-studied alternatives.
Metformin isn't FDA-approved for PCOS but is used off-label to improve insulin sensitivity and ovulation. Learn required monitoring and dosing basics.
Metformin is used off-label for weight maintenance after initial weight loss. Review the clinical trial evidence, required lab monitoring, dosing protocols, and safety considerations for long-term use.
A clinical evidence summary of tirzepatide (Mounjaro) for heart failure, including SURMOUNT-HFpEF trial data, mechanism of action, current FDA-approved indications, and what the research means for patients with HFpEF.
Can Mounjaro (tirzepatide) be used for heart failure? Review the clinical trial data, off-label status, monitoring requirements, and what cardiologists recommend for HFpEF patients.
Tirzepatide (Mounjaro) is prescribed off-label for PCOS. Review the dosing protocol, clinical evidence for insulin resistance and ovulation, FDA status, and what the research actually shows.
Tirzepatide (Mounjaro) is not FDA-approved for PCOS, but emerging trial data suggest meaningful improvements in ovulation, insulin resistance, and androgen levels. Here is what clinicians and patients should know about the risks and tradeoffs.
Tirzepatide (Mounjaro) is being used off-label for obstructive sleep apnea. Review the SURMOUNT-OSA trial data, dosing protocols, AHI reductions, and what clinicians should know before prescribing.
A clinical evidence summary of tirzepatide (Mounjaro) used off-label for weight loss, including trial data from SURMOUNT and SURPASS, dosing, safety, and how it compares to semaglutide.
Semaglutide (Ozempic) 0.5-2.0 mg is being explored off-label for heart failure. Review the dosing protocol, trial evidence from SELECT and STEP-HFpEF, FDA-approved indications, and what clinicians should know.
Semaglutide (Ozempic) is not FDA-approved for heart failure, but emerging trial data in HFpEF shows measurable benefits. Learn the evidence, monitoring protocols, and safety considerations for off-label use.
Semaglutide (Ozempic) 0.5-2.0 mg is being studied for kidney protection in CKD. Review the off-label evidence, dosing protocols, FLOW trial results, and clinical guidance for renal use.
Semaglutide (Ozempic) 0.5 to 2.0 mg is used off-label for NASH. Review the dosing protocol, key trial data, FDA status, and what clinicians should know before prescribing.
Semaglutide (Ozempic) is not FDA-approved for NASH/MASH, but clinical trial data shows histological improvement in liver fibrosis and steatohepatitis. Learn the risks, dosing, and evidence.
Semaglutide (Ozempic) is used off-label for PCOS to improve insulin resistance, restore ovulation, and reduce androgen levels. Learn the dosing protocol, evidence base, and what clinicians should discuss with patients.
A evidence summary of off-label semaglutide (Ozempic) for polycystic ovary syndrome (PCOS), covering trial data on weight, androgens, ovulation, and insulin resistance.
Ozempic (semaglutide 0.5-2.0 mg) is FDA-approved for type 2 diabetes, not weight loss. Here's what the clinical trials show about off-label use, real risks, and how it compares to the approved weight-loss dose.
A clinical evidence summary of bremelanotide (PT-141) for male sexual dysfunction, including trial data, dosing, safety, and off-label status.
Liraglutide 3 mg (Saxenda) is being studied off-label for alcohol use disorder. This evidence summary covers preclinical data, early clinical trials, mechanism of action, and what clinicians should know.
Liraglutide 3 mg (Saxenda) is sometimes used off-label for binge eating disorder. This article reviews the evidence, dosing protocol, safety considerations, and how it compares to FDA-approved BED treatments.
Can liraglutide 3 mg (Saxenda) treat binge eating disorder? Review of clinical trials, dosing, off-label evidence, and what the research actually shows about GLP-1 receptor agonists for BED.
Can Saxenda (liraglutide 3 mg) treat binge eating disorder? Review the off-label evidence, clinical trial data, risks, and how GLP-1 receptor agonists affect binge eating behavior.
Liraglutide 3 mg (Saxenda) is used off-label for NASH. Review the dosing protocol, LEAN trial evidence, histological outcomes, and practical clinical considerations.
Sermorelin acetate is used off-label for adult growth hormone deficiency. This guide covers the evidence, risks, dosing, and how it compares to FDA-approved recombinant GH therapy.
A clinical review of sermorelin acetate for sleep improvement, including its off-label status, the link between growth hormone and sleep architecture, and what published trials report.
TB-500 (thymosin beta-4 active fragment) is used off-label for wound healing. Review the preclinical evidence, proposed dosing protocols, safety considerations, and FDA status.
A clinical evidence review of TB-500 (thymosin beta-4 active fragment) for wound healing, including preclinical data, off-label use context, dosing protocols, and safety considerations.
Evidence-based guide to off-label testosterone cypionate use in frailty syndrome, covering dosing protocols, clinical trial data, safety monitoring, and guideline recommendations.
Evidence-based guide to off-label testosterone cypionate use in gender-affirming hormone therapy, including dosing protocols, monitoring, and clinical outcomes.
A clinical evidence summary of testosterone cypionate used off-label for gender-affirming hormone therapy, including dosing, outcomes, safety data, and guideline recommendations.
Testosterone cypionate is widely used off-label for gender-affirming hormone therapy. Learn about evidence, dosing, risks, monitoring, and what the Endocrine Society guidelines recommend.
Evidence-based guide to off-label testosterone cypionate use in HIV wasting syndrome, including dosing protocols, clinical trial data, and monitoring requirements.
Testosterone cypionate is used off-label for HIV-associated wasting syndrome. Review the clinical evidence, dosing protocols, risks, and how it compares to FDA-approved therapies.
Can semaglutide 2.4 mg (Wegovy) treat alcohol use disorder? Review the preclinical and early clinical evidence, proposed dosing protocols, and what physicians should know before prescribing off-label.
Semaglutide 2.4 mg (Wegovy) is being used off-label for binge eating disorder. Review the clinical evidence, monitoring protocols, and what patients and clinicians should track during treatment.